Edition:
United States

Lannett Company Inc (LCI.N)

LCI.N on New York Stock Exchange

22.30USD
27 Mar 2017
Change (% chg)

$0.85 (+3.96%)
Prev Close
$21.45
Open
$21.35
Day's High
$22.70
Day's Low
$21.20
Volume
104,227
Avg. Vol
182,585
52-wk High
$39.95
52-wk Low
$16.75

Latest Key Developments (Source: Significant Developments)

Lannett Co says FDA agreed to delay submission deadline for Methylphenidate ER tablets
Wednesday, 22 Feb 2017 06:54am EST 

Lannett Company Inc : Lannett provides further update on methylphenidate er tablets . Lannett company inc- FDA agreed to delay submission deadline for Methylphenidate ER tablets . Lannett company-FDA suspended deadline to submit materials in support of its request for hearing to consider FDA's proposal co withdraw ANDA for Methylphenidate ER . Lannett co-FDA expected to discuss sufficiency of documents related to Methylphenidate ER tablets with co once documents are released .Lannett co-FDA expected to establish new dates for submission of materials in support of hearing request.  Full Article

Lannett's subsidiary to launch $50 mln expansion - SEC filing
Tuesday, 31 Jan 2017 08:51am EST 

Lannett Company Inc :Lannett Company Inc - Cody Laboratories, a wholly owned subsidiary of company, would be launching a $50 million expansion to its facilities - SEC filing.  Full Article

Lannett announces approval for memantine hydrochloride tablets USP, 5 mg and 10 mg
Monday, 14 Nov 2016 06:56am EST 

Lannett Company Inc : Lannett announces approval for memantine hydrochloride tablets usp, 5 mg and 10 mg .Lannett company inc - "expect to commence marketing product in approximately two months".  Full Article

Lannett reports fiscal 2017 Q1 financial results
Thursday, 3 Nov 2016 04:15pm EDT 

Lannett Company Inc : Lannett Company Inc - Revises guidance for fiscal 2017 . Lannett Company Inc sees 2017 GAAP net sales $675 million to $685 million; down from $690 million to $700 million . Lannett Company Inc sees 2017 non-GAAP net sales $675 million to $685 million; down from $690 million to $700 million . Lannett Company Inc sees 2017 GAAP gross margin in range of 51.5% to 52.5%, up from 50% to 51% . Lannett Company Inc sees 2017 adjusted gross margin between 57.5% to 58.5%; up from 55% to 56% . FY2017 revenue view $683.1 million -- Thomson Reuters I/B/E/S . Lannett reports fiscal 2017 first-quarter financial results . Q1 adjusted earnings per share $0.77 . Q1 loss per share $0.80 . Q1 sales $162 million versus I/B/E/S view $166.7 million .Q1 earnings per share view $0.71 -- Thomson Reuters I/B/E/S.  Full Article

Lannett Q4 adjusted earnings per share $0.73
Tuesday, 23 Aug 2016 04:15pm EDT 

Lannett Company Inc : Lannett announces record net sales for fiscal 2016 fourth-quarter and full-year . Q4 adjusted earnings per share $0.73 . Q4 earnings per share $0.10 . Q4 sales $168.9 million versus i/b/e/s view $161.6 million . Q4 earnings per share view $0.59 -- Thomson Reuters I/B/E/S . Lannett Company Inc Sees fiscal 2017 capital expenditures $55 million to $65 million . Lannett Company Inc sees FY 2017 net sales to be between $690 million and $700 million . Lannett company inc sees fiscal 2017 gaap gross margin percentage 50% to 51% .Lannett Company Inc sees fiscal 2017 adjusted gross margin percentage 55% to 56%.  Full Article

Lannett provides update on application for generic Fentanyl patch
Wednesday, 20 Jul 2016 06:57am EDT 

Lannett Company Inc : Lannett announces receipt of FDA Acceptable for Filing letter for Fentanyl Patch ANDA . Under agreement, Sparsha Pharma USA will manufacture product and Lannett will be responsible for distribution .Strategic partner, Sparsha Pharma USA Inc, has received an acceptable for filing letter from FDA for Fentanyl Patch ANDA.  Full Article

Lannett company announces approval, launch for Paroxetine Extended Release Tablets USP
Monday, 11 Jul 2016 06:54am EDT 

Lannett Company Inc : Lannett announces approval and launch of Paroxetine Extended Release Tablets USP, 12.5 mg, 25 mg, 37.5 mg ."Fiscal 2017, which began on July 1, 2016, is currently exceeding our expectations".  Full Article

Lannett Co enters into amendment No. 1 to credit, guaranty agreement
Monday, 20 Jun 2016 04:44pm EDT 

Lannett Company Inc : On June 17, Lannett entered into amendment No. 1 to credit and guaranty agreement - sec filing . Pursuant to amendment, Lannett was provided incremental term loan by incremental term lender in principal amount of $150.0 million . Senior credit facility consisted of term loan facility initially providing for tranche a term loans in aggregate amount of $275 million . Used proceeds of incremental term loan, to repurchase remaining outstanding $200 million amount of Lannett's 12.0% senior notes due 2023 . Senior credit facility consisted of term loan facility providing for tranche b term Loans&Tranche a term loans in aggregate amount of $635 million .Senior secured credit facility includes revolving credit facility providing for revolving loans in aggregate amount of up to $125 million.  Full Article

Lannett to amend credit agreement to repurchase remaining $200 mln of 12 pct senior notes
Tuesday, 14 Jun 2016 06:54am EDT 

Lannett Company Inc : Lannett to amend credit agreement to repurchase remaining $200 million of 12% senior notes . Agreement with an existing lender to raise an incremental $150 million term loan b . Company intends to use proceeds of incremental term loan b and cash on hand to repurchase remaining $200 million of 12% senior notes due in 2023 . Incremental term loan b is expected to have terms consistent with company's existing term loan b .Cumulative effect of actions through maturity date of loans is expected to generate cash interest savings of approximately $170 million.  Full Article

Lannett receives FDA approval for neomycin sulfate tablets USP, 500 mg
Monday, 13 Jun 2016 06:57am EDT 

Lannett Company Inc : Lannett receives FDA approval for neomycin sulfate tablets USP, 500 mg . Expect to commence marketing product in next several months .Approval of ANDA for neomycin sulfate tablets USP, 500 mg, equivalent to neomycin sulfate tablets USP, 500 mg, of Teva Pharmaceuticals USA.  Full Article

More From Around the Web